These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, development and commercialization of enhanced technologies, product performance, clinical outcomes, our business plans and competitive offerings.
These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For more information, please visit: Cautionary Statement Regarding Forward-Looking Statements Food and Drug Administration, and are currently not available for sale in the United States.īoston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.
The INGENIO and ADVANTIO pacemakers are currently under review by the U.S. The system will detect clinical events between scheduled visits and send relevant data directly to a secure physician-accessible website via landline or cellular-based telephone technology. The INGENIO family of pacemakers and CRT-Ps will be compatible with Boston Scientific’s new LATITUDE™ NXT Remote Patient Management system, which will enable physicians to conduct remote follow-ups of these device patients to monitor specific pacemaker information and heart health status. “The new RightRate pacing is easy to optimize and will provide needed heart rates for patients to help them feel less fatigued during physical activity.” “The INGENIO device enables physicians to treat pacemaker patients with an advanced and comprehensive set of therapies,” said Marc Burban, M.D., a physician who implanted one of the first INGENIO devices. RightRate employs Boston Scientific’s minute ventilation (MV) sensor, the only sensor clinically proven to restore chronotropic competence, and adds programming options to promote ease of use and in-clinic time savings. CI is the inability of the heart to regulate its rate appropriately in response to physical activity, which may cause patients to feel tired or short of breath during daily activities such as walking or going up a flight of stairs. The INGENIO and ADVANTIO pacemakers also feature RightRate™ pacing technology designed to treat chronotropic incompetence (CI). Pacemakers are designed to treat bradycardia, a condition in which the heart beats too slowly - usually less than 60 beats per minute - depriving the body of sufficient oxygen.
#RECUPERER DONNEES CLE USB SECURE AEGUS SERIES#
“In addition, we are planning to launch a series of devices that will have expanded capabilities, which will include remote monitoring, advanced heart failure diagnostics and compatibility with magnetic resonance imaging systems – all designed to provide innovative new features for patient health and well-being.” “The INGENIO family of pacemakers represents a significant investment in long-term innovation for pacing technologies and defines a new era of pacing for our company,” said Joe Fitzgerald, senior vice president and president of the Boston Scientific Cardiac Rhythm Management group. Marc Burban, at the Nouvelles Cliniques Nantaises in Nantes, France. One of the first implants of the INGENIO pacemaker occurred last week by Dr. Natick, MA (April 10, 2012) - Boston Scientific Corporation (NYSE: BSX) announces CE mark approval and European market launch of its INGENIO™ and ADVANTIO™ pacemakers and INVIVE™ cardiac resynchronization therapy pacemakers (CRT-P).
English to French: BOSTON SCIENTIFIC announces launch of ingenio™ FAMILY OF pacemakers in europeīOSTON SCIENTIFIC announces launch of ingenio™ FAMILY OF pacemakers in europeĪdvanced devices designed to treat chronotropic incompetence, which affects up to 42 percent
0 kommentar(er)
